Table 1.

Treatment-emergent adverse events with an incidence of > 1 in treatment groups after a single oral dose of JNJ-61803534, follow-up 42–57 days.

	Placebo n = 12	10 mg n = 6	30 mg n = 6	100 mg (fasted) n = 9	100 mg (fed) n = 9	200 mg n = 6
Diarrhea	0	0	0	2	2	0
Aphthous ulcer	0	0	0	0	1	1
Medical device site reaction	1	0	1	2	2	1
Back pain	0	1	0	1	1	1
Musculoskeletal discomfort	0	0	0	0	0	2
Viral upper respiratory tract infection	1	0	0	2	2	0
Oral herpes	0	0	1	0	1	0
Headache	2	0	1	4	0	0
Hypercholesterolaemia	1	0	0	2	0	1
Nasal congestion	0	0	0	2	0	0